Charm Therapeutics

Developer of menin inhibitors designed for acute myeloid leukemia treatment

placeLondon, England, United Kingdom calendar_todayFounded 2021 groups16 employees language charmtx.com

Registered entities

Social engagement

Social engagement: 13.1K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

13 investors on record; lead investors include F-Prime Capital, Orbimed, New Enterprise Associates, SR One.

Investor typeCountShare
Venture capital1077%
Bank & private debt18%
Other / undisclosed215%

Recent activity

10 Jun 2026
Event
European Hematology Association (EHA) Congress
13 Nov 2025
Product launch
CHM-029
11 Nov 2025
Event
LSX Investival Showcase panel
Coming soon